The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

DR. COHEN SAYS THAT DOESN'T MEAN GREATER ACCESS TO THEM.. AS DEMAND GOES UP.. BUT HE SA Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been ...

AS DEMAND GOES UP.. BUT HE SA Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the U.S. Food and Drug Administration to ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...